1. Department of GI Medical Oncology ALPHABET SOUP: MAKING SENSE OF KRAS, BRAF, RAS AND OTHER BIOMARKERS IN METASTATIC COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate…

Slide 1Part 2 Colorectal Cancer Thursday, July 26, 2012 7:30 PM – 8:30 PM ET RTP TV: Emerging Treatment Strategies in Colorectal Cancer Slide 2 Richard M Goldberg, MD Professor…

Slide 11 www.cinbo.org O n c o l o Together for y LOncologia insieme per L*Aquila G Bruera, D Di Giacomo & E Ricevuto Medical Oncology Department Experimental Medicine…

1. Welcome!Whats New in Colorectal Cancer Research?Part of Fight Colorectal Cancer’s Monthly Patient Webinar Series Our webinar will begin shortlywww.FightColorectalCancer.orgwww.CCAlliance.org877-427-2111…

An Application of Evidence-Based Marginal Analysis: Assessing the Incremental Cost Effectiveness of Eras of Metastatic Colorectal Cancer Therapy in British Columbia, Canada:…

Slide 1Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority…

Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic colorectal…

Slide 1 Bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international…

* Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG)…

Slide 1 Bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international…